Nephrotic syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Nephrotic syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Nephrotic syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Nephrotic syndrome: Overview
Nephrotic syndrome is a group of symptoms that show your kidneys are not working as well as they should. These symptoms include too much protein in your urine, not enough protein in your blood, too much fat or cholesterol in your blood, and swelling. Anyone can get nephrotic syndrome but it is slightly more common in men than in women. In children, it happens most often between the ages of 2 and 6. The most common primary cause of nephrotic syndrome in adults is a disease called focal segmental glomerulosclerosis (FSGS). The only way to know for sure whether you have FSGS is to get a kidney biopsy. Even when treated, most people with FSGS will eventually develop kidney failure and will need to start dialysis or have a kidney transplant to live. After transplant, there is still a chance that FSGS will return and you may lose your new kidney.
'Nephrotic syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nephrotic syndrome pipeline landscape is provided which includes the disease overview and Nephrotic syndrome treatment guidelines. The assessment part of the report embraces, in depth Nephrotic syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nephrotic syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Nephrotic syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nephrotic syndrome Emerging Drugs
Further product details are provided in the report.
Nephrotic syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Nephrotic syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Nephrotic syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nephrotic syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nephrotic syndrome drugs.
Nephrotic syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Nephrotic syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Nephrotic syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Nephrotic syndrome: Overview
Nephrotic syndrome is a group of symptoms that show your kidneys are not working as well as they should. These symptoms include too much protein in your urine, not enough protein in your blood, too much fat or cholesterol in your blood, and swelling. Anyone can get nephrotic syndrome but it is slightly more common in men than in women. In children, it happens most often between the ages of 2 and 6. The most common primary cause of nephrotic syndrome in adults is a disease called focal segmental glomerulosclerosis (FSGS). The only way to know for sure whether you have FSGS is to get a kidney biopsy. Even when treated, most people with FSGS will eventually develop kidney failure and will need to start dialysis or have a kidney transplant to live. After transplant, there is still a chance that FSGS will return and you may lose your new kidney.
'Nephrotic syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nephrotic syndrome pipeline landscape is provided which includes the disease overview and Nephrotic syndrome treatment guidelines. The assessment part of the report embraces, in depth Nephrotic syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nephrotic syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nephrotic syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Nephrotic syndrome.
This segment of the Nephrotic syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nephrotic syndrome Emerging Drugs
- Belimumab: GlaxoSmithKline
Further product details are provided in the report.
Nephrotic syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Nephrotic syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Nephrotic syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Nephrotic syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nephrotic syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nephrotic syndrome drugs.
Nephrotic syndrome Report Insights
- Nephrotic syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nephrotic syndrome drugs?
- How many Nephrotic syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nephrotic syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nephrotic syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nephrotic syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlaxoSmithKline
- Goldfinch Bio, Inc.
- Travere Therapeutics, Inc.
- Aurinia Pharmaceuticals
- Bristol-Myers Squibb
- ChemoCentryx
- SynAct Pharma AB
- Belimumab
- GFB-887
- RE-021
- Voclosporin
- Abatacept
- AP1189
Introduction
Executive Summary
Nephrotic syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nephrotic syndrome – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
Belimumab: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Nephrotic syndrome Key Companies
Nephrotic syndrome Key Products
Nephrotic syndrome- Unmet Needs
Nephrotic syndrome- Market Drivers and Barriers
Nephrotic syndrome- Future Perspectives and Conclusion
Nephrotic syndrome Analyst Views
Nephrotic syndrome Key Companies
Appendix
Introduction
Executive Summary
Nephrotic syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nephrotic syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nephrotic syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nephrotic syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Belimumab: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Nephrotic syndrome Key Companies
Nephrotic syndrome Key Products
Nephrotic syndrome- Unmet Needs
Nephrotic syndrome- Market Drivers and Barriers
Nephrotic syndrome- Future Perspectives and Conclusion
Nephrotic syndrome Analyst Views
Nephrotic syndrome Key Companies
Appendix
Executive Summary
Nephrotic syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nephrotic syndrome – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
Belimumab: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Nephrotic syndrome Key Companies
Nephrotic syndrome Key Products
Nephrotic syndrome- Unmet Needs
Nephrotic syndrome- Market Drivers and Barriers
Nephrotic syndrome- Future Perspectives and Conclusion
Nephrotic syndrome Analyst Views
Nephrotic syndrome Key Companies
Appendix
Introduction
Executive Summary
Nephrotic syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nephrotic syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nephrotic syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nephrotic syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Belimumab: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Nephrotic syndrome Key Companies
Nephrotic syndrome Key Products
Nephrotic syndrome- Unmet Needs
Nephrotic syndrome- Market Drivers and Barriers
Nephrotic syndrome- Future Perspectives and Conclusion
Nephrotic syndrome Analyst Views
Nephrotic syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Nephrotic syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Nephrotic syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Nephrotic syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Nephrotic syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
